![]() ![]() Through a consensus-driven process, Summit participants identified seven opportunities as the most feasible and impactful for achieving closer integration of pathology with the cancer team. Through panel discussions, breakout group conversations, and interactive presentations, Summit participants shared perspectives on how pathology is currently integrated with the multidisciplinary cancer care team and what opportunities exist to improve on the status quo. Summit Executive Summary Summit Proceedings Generating "One Standardized Pathology Report".Strengthening the alliance between pathology & genetic counseling.Optimizing virtual molecular tumor boards.Standardizing the testing order process.Empowering pathologists & the oncology team for culture change.Leadership Summit participants prioritized future opportunities, identifying the following as the most immediately actionable: This invitation-only forum convened a select group of thought leaders from a diverse group of stakeholders including providers, payers, patient advocacy groups, labs, diagnostic and tech companies, and pharmaceutical manufacturers to discuss critical issues facing the oncology community with regards to biomarker testing, precision medicine, and the current ways in which pathologists interface with the cancer care team.Äownload the Environmental Scan Learn About the Summit Participants These materials, along with a paper highlighting key policy issues, comprised pre-reading for participants attending the Integration of Pathology in Oncology Care Leadership Summit held on July 31, 2018, in Washington, D.C. There are currently no formally established criteria to classify the levels of integration between pathology and the multidisciplinary cancer care team. Recent advances in targeted therapies, molecular biology, and immuno-oncology necessitate a closer integration and coordination of pathology with the multidisciplinary cancer care team. PATHOLOGY CANCER TRIALPathologists may also play a role in determining clinical trial eligibility, especially for patients who do not respond to the standard of care. As clinicians monitor treatment response, repeat biopsies or biomarker testing may inform how the tumor is evolving. Starting at the point of cancer diagnosis, pathologists provide expert interpretation and may recommend biomarker testing to guide treatment decisions. Pathologists are uniquely positioned at the intersection of multiple points along the cancer care continuum. In an era of precision medicine and rapidly advancing cancer therapeutics, the role of pathology in the diagnosis and management of cancer is evolving. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |